A novel cardiac phenotype in patients with GFPT1 or DPAGT1 mutations

Experimental and Clinical Cardiology

Volumn 20, Issue 8, 2014, Pages 3139-3145

  Lewis, Andrew J M ^a   Finlayson, Sarah ^b,c   Mahmod, Masliza ^a   Karamitsos, Theodoros D ^a   Dass, Sairia ^a   Ashrafian, Houman ^a   Francis, Jane M ^a   Watkins, Hugh ^a   Beeson, David ^c   Palace, Jacqueline ^b   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiomyopathy; Genes; Glycoproteins; Magnetic resonance imaging

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; GADOLINIUM; GADOTERATE MEGLUMINE;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CONGENITAL MYASTHENIC SYNDROME; CONTRAST ENHANCEMENT; DIASTOLIC DYSFUNCTION; DPAGT1 GENE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GENE; GENE MUTATION; GFPT1 GENE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REAL TIME ULTRASOUND SCANNER;

EID: 84905833865     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Zoltowska K, Webster R, Finlayson S, Maxwell S, Cossins J, Müller J, et al., Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR. Human molecular genetics. 2013;22(14):2905-13.
2. Belaya K, Finlayson S, Slater C R, Cossins J, Liu W W, Maxwell S, et al., Mutations in DPAGT1 Cause a Limb-Girdle Congenital Myasthenic Syndrome with Tubular Aggregates. American Journal of Human Genetics. 2012;91(1):193.
3. Senderek J, Müller J S, Dusl M, Strom T M, Guergueltcheva V, Diepolder I, et al., Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. The American Journal of Human Genetics. 2011;88(2):162-172.
4. Clayton P, Winchester B, and Keir G, Hypertrophic obstructive cardiomyopathy in a neonate with the carbohydrate-deficient glycoprotein syndrome. Journal of inherited metabolic disease. 1992;15(6):857-861. (Pubitemid 23023187)
5. Al-Owain M, Mohamed S, Kaya N, Zagal A, Matthijs G, and Jaeken J, A novel mutation and first report of dilated cardiomyopathy in ALG6-CDG (CDG-Ic): a case report. Orphanet Journal of Rare Diseases. 2010;5(1):7.
6. Marquardt T, Hülskamp G, Gehrmann J, Debus V, Harms E, and Kehl H, Severe transient myocardial ischaemia caused by hypertrophic cardiomyopathy in a patient with congenital disorder of glycosylation type Ia. European journal of pediatrics. 2002;161(10):524-527.
7. Belaya K, Finlayson S, Cossins J, Liu W W, Maxwell S, Palace J, et al., Identification of DPAGT1 as a new gene in which mutations cause a congenital myasthenic syndrome. Annals of the New York Academy of Sciences. 2012;1275(1):29-35.
8. Tyler D, Emmanuel Y, Cochlin L, Hudsmith L, Holloway C, Neubauer S, et al., Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T. NMR in biomedicine. 2009;22(4):405-413.
9. Nagueh S F, Appleton C P, Gillebert T C, Marino P N, Oh J K, Smiseth O A, et al., Recommendations for the evaluation of left ventricular diastolic function by echocardiography. European Journal of Echocardiography. 2009;10(2):165-193.
10. Hudsmith L E, Petersen S E, Francis J M, Robson M D, and Neubauer S, Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance. 2005;7(5):775-782. (Pubitemid 41770055)
11. Phan T and Frenneaux M, The pathophysiology of diastolic heart failure. F1000 biology reports. 2009;2:317-334.
12. Zile M R and Brutsaert D L, New concepts in diastolic dysfunction and diastolic heart failure: part ii causal mechanisms and treatment. Circulation. 2002;105(12):1503-1508. (Pubitemid 34263285)
13. Galderisi M, Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovascular ultrasound. 2005;3(1):9.
14. Iqbal Z, Shahzad M, Vissers L, van Scherpenzeel M, Gilissen C, Razzaq A, et al., A compound heterozygous mutation in DPAGT1 results in a congenital disorder of glycosylation with a relatively mild phenotype. European journal of human genetics. 2012;21:844-849.
15. Footitt E, Karimova A, Burch M, Yayeh T, Dupre T, Vuillaumier-Barrot S, et al., Cardiomyopathy in the congenital disorders of glycosylation (CDG): a case of late presentation and literature review. Journal of inherited metabolic disease. 2009;32(1):313-319.
16. Lefeber D J, Morava E, and Jaeken J, How to find and diagnose a CDG due to defective N-glycosylation. Journal of inherited metabolic disease. 2011;34(4):849-852.
17. Lefeber D J, de Brouwer A P M, Morava E, Riemersma M, Schuurs-Hoeijmakers J H M, Absmanner B, et al., Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS genetics. 2011;7(12):e1002427.
18. Clark R J, McDonough P M, Swanson E, Trost S U, Suzuki M, Fukuda M, et al., Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear OGlcNAcylation. Journal of Biological Chemistry. 2003;278(45):44230-44237. (Pubitemid 37377167)
19. Fricovsky E S, Suarez J, Ihm S-H, Scott B T, Suarez-Ramirez J A, Banerjee I, et al., Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2012;303(7):689-699.
20. Gehmann J, Sohlbach K, Linnebank M, Bobles H, Buderus S, Gerd Kehl H, et al., Cardiomyopathy in congenital disorders of glycosylation. Cardiology in the Young. 2003;13(4):345-351. (Pubitemid 41630874)
21. Coral-Vazquez R, Cohn R D, Moore S A, Hill J A, Weiss R M, Davisson R L, et al., Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 1999;98(4):465-474. (Pubitemid 29402484)
22. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, et al., Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proceedings of the National Academy of Sciences. 1997;94(25):13873-13878. (Pubitemid 28009677)
23. Barresi R, Di Blasi C, Negri T, Brugnoni R, Vitali A, Felisari G, et al., Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β sarcoglycan mutations. Journal of medical genetics. 2000;37(2):102-107. (Pubitemid 30245892)
24. Tsubata S, Bowles K R, Vatta M, Zintz C, Titus J, Muhonen L, et al., Mutations in the human deltasarcoglycan gene in familial and sporadic dilated cardiomyopathy. Journal of Clinical Investigation. 2000;106(5):655-662.
25. Bies R D, Maeda M, Roberds S L, Holder E, Bohlmeyer T, Young J B, et al., A 5′ Dystrophin Duplication Mutation Causes Membrane Deficiency of< i> α-Dystroglycan in a Family with X-linked Cardiomyopathy. Journal of molecular and cellular cardiology. 1997;29(12):3175-3188. (Pubitemid 28039353)
26. Suttie J J, Dass S, Karamitsos T D, Holloway C J, Cochlinl L E, Francis J M, et al., Becker and Duchenne Muscular Dystrophy (BMD, DMD) are associated with myocardial fibrosis and abnormal cardiac energetics even in the presence of normal left ventricular ejection fraction. Journal of Cardiovascular Magnetic Resonance. 2010;12:1-2.
27. Liewluck T, Selcen D, and Engel A G, Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle & nerve. 2011;44(5):789-794.
28. Lashley D, Palace J, Jayawant S, Robb S, and Beeson D, Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology. 2010;74(19):1517-1523.